 Similar research that Boger utilized for comparison to his results involving elimination of cancerous tumors and antigens was centered around the use of similar immunoconjugates that were introduced to cancerous colon cells.These studies related to Boger's research involving antigen-specificity that is necessary to the success of the duocarmycins as antitumor treatments.The duocarmycin analogues are able to exert their mode of action at any phase in the cellular cycle, whereas tubulin binders will only attack tumor cells when they are in a mitotic state.